enter passkey to continue
incorrect passkey
Sequence ONC is a structured, evidence-based clinical program that transforms hereditary cancer genetic testing from an isolated lab order into a bundled care episode with measurable cancer prevention outcomes. Every patient identified enables cascade screening of an entire family.
An estimated 5–10% of all cancers are driven by inherited germline mutations. These patients are identifiable before they develop cancer, yet the majority are diagnosed only after a preventable malignancy occurs. For payers, every missed hereditary cancer carrier represents avoidable catastrophic claims.
Approximately 1 in 400 individuals carry a BRCA1/2 pathogenic variant. Lynch syndrome affects an estimated 1 in 279. Together with Li-Fraumeni, FAP, VHL, MEN, Cowden, CDH1, and additional syndromes, hereditary cancer represents one of the most prevalent and actionable categories of genetic disease in any insurer's covered population.
Studies show that fewer than 20% of individuals who meet NCCN criteria for hereditary cancer genetic testing are ever referred for evaluation. This gap persists across commercial, Medicare, and Medicaid populations. Each untested qualifying patient represents a family in which cancer prevention is deferred until a malignancy triggers a retrospective workup.
When a hereditary cancer mutation is identified, each first-degree relative has a 50% chance of carrying the same variant. A single $250 targeted test can clarify risk for 3–5 additional family members. Without systematic cascade testing programs, this multiplier effect is lost and entire families remain unaware of actionable cancer risk.
Late-stage cancer treatment costs $100,000–$500,000+ per patient. Risk-reducing surgery for a BRCA carrier costs $15,000–$30,000 and eliminates the cancer risk entirely. Genetic testing ($250–$3,000) plus cascade screening is among the most cost-effective interventions in all of medicine, with published ICER ratios well below standard willingness-to-pay thresholds.
The CarePathway bundles risk assessment, genetic testing, result interpretation, risk management, and cascade screening into a single, measurable care episode. For payers, this replaces fragmented, ad hoc test authorizations with a structured program tied to cancer prevention outcomes.
Systematic identification of individuals meeting NCCN genetic testing criteria through personal cancer history, family history scoring (three-generation pedigree), ancestry-based risk factors, and tumor characteristics (triple-negative breast cancer, MSI-high colorectal cancer, young-onset malignancy). Red flag triggers include early-onset cancer, multiple primary cancers, and clustering of related cancers across generations. Patients not meeting criteria are documented and returned to standard screening.
Pre-test genetic counseling establishes informed consent, sets expectations, and addresses psychosocial considerations. Test selection follows syndrome-specific logic: multigene panel testing for broad hereditary cancer evaluation, single-gene testing for known familial variants, and reflex testing when initial results require expanded analysis. Post-test counseling delivers results with variant interpretation and actionable next steps for pathogenic, negative, and VUS findings.
Positive results trigger syndrome-specific management: NCCN-guideline high-risk surveillance protocols (enhanced breast MRI, accelerated colonoscopy schedules), risk-reducing surgery consultation (prophylactic mastectomy, salpingo-oophorectomy, colectomy, thyroidectomy), chemoprevention evaluation (tamoxifen, aspirin for Lynch syndrome), immunotherapy eligibility assessment for MSI-H/dMMR tumors, and reproductive counseling. Every recommendation maps to published evidence for cancer risk reduction.
The identified familial variant becomes the anchor for cascade screening of at-risk relatives. Genetic counseling coordinates outreach to first- and second-degree relatives, offers targeted single-site testing ($250 per relative), and enrolls positive family members into the same risk management pathway. Each proband generates 3–5 additional testable family members, creating a multiplicative cancer prevention effect. Population screening integration extends identification beyond family-history-based approaches.
Each syndrome has defined genetic etiology, established testing criteria, published penetrance data, and NCCN-guideline management recommendations. These are precision diagnostics with direct clinical consequences.
Hereditary breast and ovarian cancer syndrome. BRCA1 carriers face 45–72% lifetime breast cancer risk and 39–44% ovarian cancer risk. BRCA2 confers 45–69% breast and 11–17% ovarian risk. Risk-reducing salpingo-oophorectomy reduces ovarian cancer risk by 80%. High-risk testing yield: 10–20% pathogenic.
Pathogenic variants in MLH1, MSH2, MSH6, PMS2, or EPCAM. Confers 40–80% lifetime CRC risk and 25–60% endometrial cancer risk, plus elevated ovarian, gastric, and urinary tract cancer risk. Colonoscopy every 1–2 years from age 20–25 reduces CRC mortality by over 60%. Testing yield in CRC meeting criteria: 3–5%.
Among the most penetrant cancer predisposition syndromes. Carriers face near-complete lifetime cancer risk with diverse tumor spectrum: sarcomas, breast cancer, brain tumors, adrenocortical carcinoma, leukemia. Whole-body MRI surveillance protocols (Toronto Protocol) enable early detection across organ systems.
Familial adenomatous polyposis (classic and attenuated). Classic FAP causes hundreds to thousands of colorectal polyps with near-certain CRC without prophylactic colectomy. Attenuated FAP (AFAP) presents with fewer polyps but still confers significantly elevated CRC risk. Early colonoscopy and surgical planning are definitive prevention.
Pathogenic VHL variants cause renal cell carcinoma, hemangioblastomas (CNS, retinal), pheochromocytoma, and pancreatic neuroendocrine tumors. Lifetime renal cancer risk exceeds 70%. Structured surveillance with annual imaging enables organ-sparing surgery and prevents metastatic disease.
PTEN pathogenic variants confer elevated risk for breast cancer (85% lifetime), thyroid cancer (35%), endometrial cancer (28%), colorectal cancer (9%), and renal cancer (34%). Enhanced multi-organ screening protocols reduce cancer-related mortality when patients are identified before diagnosis.
CDH1 pathogenic variants confer 70–80% lifetime risk of diffuse gastric cancer and 40–60% lobular breast cancer risk in women. Prophylactic total gastrectomy is the definitive risk-reducing intervention. CDH1 testing is indicated in families with diffuse gastric cancer diagnosed before age 50 or multiple affected relatives.
Moderate-penetrance breast cancer susceptibility genes increasingly identified on multigene panels. PALB2 confers 33–58% lifetime breast cancer risk. ATM and CHEK2 confer 2–3x elevated risk. NCCN now provides gene-specific management recommendations including enhanced screening and risk-reducing surgery consideration for PALB2 carriers.
| Syndrome | Gene(s) | Key Cancer Risks | Testing Yield |
|---|---|---|---|
| HBOC | BRCA1/BRCA2 | Breast (45–72%), Ovarian (11–44%) | 10–20% in high-risk |
| Lynch Syndrome | MLH1/MSH2/MSH6/PMS2/EPCAM | CRC (40–80%), Endometrial (25–60%) | 3–5% in CRC meeting criteria |
| Li-Fraumeni | TP53 | Multi-organ (near-complete penetrance) | Rare; high yield in selected families |
| FAP / AFAP | APC | CRC (near-certain in classic FAP) | High in polyposis families |
| VHL | VHL | Renal (70%+), Hemangioblastoma, Pheo | High in affected families |
| Cowden / PHTS | PTEN | Breast (85%), Thyroid (35%), Endometrial (28%) | Variable by clinical criteria |
| HDGC | CDH1 | Diffuse Gastric (70–80%), Lobular Breast (40–60%) | High in qualifying families |
| Moderate-Penetrance | PALB2/ATM/CHEK2 | Breast (2–4x elevated) | 5–10% on multigene panels |
The CarePathway uses National Comprehensive Cancer Network criteria to identify patients who should be offered genetic evaluation. These criteria represent the existing, published standard of care that is systematically under-implemented.
NCCN, ASCO, ACOG, and the EGAPP Working Group all recommend universal tumor MMR testing on all newly diagnosed colorectal and endometrial cancers, regardless of age or family history. This reflexive approach identifies Lynch syndrome carriers missed by family-history-based criteria alone.
Positive genetic results trigger structured, NCCN-guided management protocols. The CarePathway maps each syndrome to specific surveillance schedules, risk-reducing surgical options, chemoprevention, and immunotherapy eligibility criteria.
Lynch syndrome tumors frequently exhibit microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR), conferring eligibility for immune checkpoint inhibitor therapy. Pembrolizumab received tumor-agnostic FDA approval for MSI-H/dMMR solid tumors. Identifying Lynch syndrome not only enables cancer prevention in the family but may alter treatment selection when cancer has already occurred, improving outcomes through precision immunotherapy.
BRCA1/2-mutated cancers are eligible for PARP inhibitor therapy (olaparib, rucaparib, niraparib, talazoparib), which exploits the homologous recombination deficiency created by BRCA loss. Germline BRCA testing is now standard of care in breast, ovarian, pancreatic, and prostate cancer to determine PARP inhibitor eligibility. Identifying the germline variant before cancer enables both prevention and optimal treatment selection if cancer develops.
Hereditary cancer genetic testing is not a cost — it is a cost-elimination strategy. Every carrier identified before cancer diagnosis converts a potential $200,000–$500,000+ catastrophic claim into a $15,000–$30,000 preventive intervention. The cascade multiplier amplifies this return across the family unit.
| Metric | Value | Payer Impact |
|---|---|---|
| Testing Cost per Proband | $250 – $3,000 | Single bundled episode payment |
| Cascade Tests per Proband | 3 – 5 relatives | $250/relative single-site testing |
| Risk-Reducing Surgery (BRCA) | $15K – $30K | One-time cost vs. lifetime cancer risk |
| Cancer Treatment Avoided | $100K – $500K+ | Per prevented malignancy |
| BRCA Ovarian Cancer Prevention | 80% risk reduction | Eliminates highest-cost cancer type |
| Lynch CRC Mortality Reduction | 60%+ with surveillance | Shifts from treatment to screening cost |
| Published ICER | Cost-effective | Below standard WTP thresholds |
The hereditary cancer CarePathway reframes genetic testing from a line-item lab charge into a utilization management strategy. By bundling risk assessment, testing, counseling, and cascade screening into a single care episode with defined endpoints, payers gain a measurable program that converts unpredictable catastrophic cancer claims into planned, lower-cost preventive interventions. The ROI is measurable within 12–24 months for high-prevalence syndromes and compounds annually through cascade screening.
Hereditary cancer management spans the continuum from risk identification to cancer prevention to long-term surveillance. The CarePathway coordinates expertise across disciplines that rarely share a care plan in conventional delivery models.
Syndrome-level diagnosis, variant interpretation, genotype-phenotype correlation, multi-syndrome risk assessment for patients with overlapping clinical features, and longitudinal genetic care coordination across the family unit.
Pre-test risk assessment, informed consent, post-test result disclosure, psychosocial support, cascade testing coordination with at-risk relatives, and VUS management including reclassification tracking.
Chemoprevention evaluation (tamoxifen, aspirin for Lynch), high-risk surveillance protocol implementation, PARP inhibitor eligibility assessment, and integration of germline findings into somatic tumor profiling for treatment selection.
Risk-reducing surgical consultation: prophylactic mastectomy, salpingo-oophorectomy, colectomy, gastrectomy, thyroidectomy. Timing and approach are genotype-specific, guided by penetrance data and patient reproductive planning.
Ovarian and endometrial cancer risk management for BRCA and Lynch carriers. Risk-reducing BSO timing, fertility preservation counseling, post-surgical hormone management, and coordination with reproductive endocrinology.
Lynch and FAP surveillance colonoscopy programs, polypectomy management, prophylactic colectomy planning, and post-surgical monitoring. Coordinates with genetics for genotype-guided colonoscopy interval recommendations.
High-risk imaging protocols: contrast-enhanced breast MRI, whole-body MRI for Li-Fraumeni (Toronto Protocol), annual renal imaging for VHL, and surveillance imaging across syndrome-specific organ systems.
Genetic risk disclosure support, cancer anxiety management, decision-making counseling for risk-reducing surgery, family communication facilitation, and longitudinal psychosocial support for carriers living with elevated lifetime cancer risk.
Sequence ONC was designed to make hereditary cancer genetic testing systematic, measurable, and economically aligned with payer incentives — transforming ad hoc test authorizations into structured cancer prevention programs.
The fundamental reframe for payers: hereditary cancer genetic testing is not a lab test you authorize — it is a utilization management program that prevents the most expensive claims in your book of business. A BRCA carrier identified before diagnosis is a $200,000+ cancer claim that never materializes. Multiply that by the cascade effect and the ROI compounds across the family unit, the plan year, and the population.
Every CarePathway episode generates structured, auditable data: testing completion rates, diagnostic yield (positive/negative/VUS), cascade testing uptake, risk-reducing intervention rates, adherence to high-risk surveillance protocols, and cancer incidence in the screened population. These endpoints enable payers to measure program performance and quantify cancer prevention in their covered lives.
The Sequence ONC CarePathway is grounded in published clinical evidence and national guideline recommendations.
For payers, health systems, and clinical genetics programs ready to move hereditary cancer testing from ad hoc authorizations to structured, value-based cancer prevention.
Explore connected specialties across the SequenceMedicine network